[HTML][HTML] Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry …
J Calderón-Parra, A Muiño-Miguez… - PloS one, 2021 - journals.plos.org
Background Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-
infections are rare. This can lead to increased complications, including antibacterial …
infections are rare. This can lead to increased complications, including antibacterial …
[HTML][HTML] ICU-Acquired Colonization and Infection Related to Multidrug-Resistant Bacteria in COVID-19 Patients: A Narrative Review
A large proportion of ICU-acquired infections are related to multidrug-resistant bacteria
(MDR). Infections caused by these bacteria are associated with increased mortality, and …
(MDR). Infections caused by these bacteria are associated with increased mortality, and …
[HTML][HTML] Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 …
H AlQahtani, S AlBilal, E Mahmoud, O Aldibasi… - Journal of Infection and …, 2022 - Elsevier
Introduction Immunomodulators, including dexamethasone (DEX), have been
recommended by the Infectious Disease Society of America (IDSA) to treat moderate …
recommended by the Infectious Disease Society of America (IDSA) to treat moderate …
[HTML][HTML] Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics
Background: Tocilizumab is a monoclonal antibody proposed to manage cytokine release
syndrome (CRS) associated with severe COVID-19. Previously published reports have …
syndrome (CRS) associated with severe COVID-19. Previously published reports have …
[HTML][HTML] Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
M Rubio-Rivas, M Ronda, A Padulles, F Mitjavila… - International Journal of …, 2020 - Elsevier
Objectives To assess the characteristics and risk factors for mortality in patients with severe
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …
coronavirus disease-2019 (COVID-19) treated with tocilizumab (TCZ), alone or in …
Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients
AJ Martin, S Shulder, D Dobrzynski… - Journal of …, 2023 - journals.sagepub.com
Background: Literature suggests that antibiotic prescribing in COVID-19 patients is high.
Currently, there are insufficient data on what drives antibiotic prescribing practices …
Currently, there are insufficient data on what drives antibiotic prescribing practices …
Antibiotic use in patients with COVID-19: a 'snapshot'Infectious Diseases International Research Initiative (ID-IRI) survey
B Beović, M Doušak, J Ferreira-Coimbra… - Journal of …, 2020 - academic.oup.com
Background Antibiotics may be indicated in patients with COVID-19 due to suspected or
confirmed bacterial superinfection. Objectives To investigate antibiotic prescribing practices …
confirmed bacterial superinfection. Objectives To investigate antibiotic prescribing practices …
[HTML][HTML] Antibiotics use in COVID-19 patients: a systematic literature review
G Granata, F Schiavone, G Pipitone, F Taglietti… - Journal of Clinical …, 2022 - mdpi.com
The issue of bacterial infections in COVID-19 patients has received increasing attention
among scientists. Antibiotics were widely prescribed during the early phase of the pandemic …
among scientists. Antibiotics were widely prescribed during the early phase of the pandemic …
[HTML][HTML] Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
IM Tleyjeh, Z Kashour, M Riaz, L Hassett… - Clinical Microbiology …, 2021 - Elsevier
Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …
[HTML][HTML] Tocilizumab in hospitalized patients with severe Covid-19 pneumonia
IO Rosas, N Bräu, M Waters, RC Go… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …